KALA BIO, Inc.

What they do

KALA historically developed therapies for rare eye diseases, with lead candidate KPI-012 for persistent corneal epithelial defects, but discontinued that program after a Phase 2b trial failed in September 2025. The company now plans to offer a dedicated, on-premises AI infrastructure platform called Researgency, licensed from Younet AI in March 2026, targeting biotechnology and pharmaceutical customers. It also aims to monetize or out-license its legacy MSC-S biologics assets, including KPI-012 and KPI-014. As of early 2026, it has essentially no revenue and is in early-stage development of the AI business.

Revenue drivers

• Legacy biologics assets (KPI-012, KPI-014) — No revenue; potential out-licensing or collaboration income, though development has ceased and value is uncertain.
• Researgency AI platform — No revenue yet; intended as a paid platform-as-a-service for on-premises AI deployment in biotech, but still in feasibility assessment.

Recent performance

Annual revenue has been zero since 2023, and net losses were $27.0 million in 2025 and $38.5 million in 2024. For the three months ended March 31, 2026, the net loss was $1.6 million, with an accumulated deficit of $696.5 million. Cash and equivalents were $1.8 million as of March 31, 2026, and total assets were $12.3 million against total liabilities of $1.6 million. Operating cash flow was negative $32.0 million in 2025.

Strategy

Management is pursuing a dual-track strategy: (i) seeking to license or partner its MSC-S biologics assets (KPI-012, KPI-014) to preserve optionality, and (ii) developing and commercializing the exclusive Researgency AI platform for on-premises, agentic AI research infrastructure. The pivot follows the CHASE trial failure, a workforce reduction of ~51%, and an Oxford Finance default that was settled in December 2025. The company raised approximately $1.2 million in November 2025 and $4.2 million in January 2026 from private placements. It is evaluating strategic alternatives for its legacy assets while assessing the commercial viability of the AI offering.

Risks

• Going concern uncertainty — The company has a history of recurring losses, negative cash flow, and very limited cash ($1.8M as of March 2026); substantial doubt about viability was only recently alleviated.
• AI business unproven — Researgency is in early-stage evaluation with no customers or revenue, and the company has no track record in AI services.
• Legacy asset monetization risk — The MSC-S portfolio (KPI-012, KPI-014) failed its primary endpoint, making out-licensing or collaboration uncertain.
• Liquidity constraints — The company had an Oxford Finance default in September 2025 (accelerated $29.1M) and has relied on small private placements to maintain operations.

Outlook

Management says it will continue evaluating strategic alternatives for legacy MSC-S assets and will pursue development of the Researgency platform. They expect the transition to impact operating expenses and capital requirements, but provide no specific financial guidance. Near-term actions depend on securing additional capital, as cash is minimal.